Brief: Heidelberg Pharma: partner RedHill announces Orphan Drug Designation for MESUPRON
26/10/2017 09:59
Oct 26 (Reuters) - HEIDELBERG PHARMA AG WL6G.DE :
* DGAP-NEWS: HEIDELBERG PHARMA AG: PARTNER REDHILL ANNOUNCES
ORPHAN DRUG DESIGNATION FOR MESUPRON
Source text for Eikon: ID:nEQ8584xya
Further company coverage: WL6G.DE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 722 0920;))
Recent news on Heidelberg Pharma AG
See all newsBrief: Heidelberg Pharma And Huadong Medicine Receive Nmpa Approval For Hdp-101 Trial In China
Germany's Heidelberg Pharma H1 sales revenue surges, driven by milestone payments
Brief: Heidelberg Pharma Says Co. And Healthcare Royalty Announce Amendment To Existing Royalty Agreement
Brief: Redhill Biopharma Secures Allowance Of Key Chinese Patent Application For Proprietary COVID-19 Treatment, RHB-107
Brief: Heidelberg Pharma Amends Royalty Financing With Healthcare Royalty